asset acquisition

The technology, called PrecisMed, is designed to detect, measure, and assess over 200 medications in a patient's bloodstream from a finger stick.

The UK Competition and Markets Authority said blocking the deal could prevent a "substantial lessening of competition" in the NGS market.

The combined company will use RNA-based tools to enhance drug development by identifying the right patients for oncology drugs and potentially improving drug response rates.

By acquiring Bothell, Washington-based Blue Heron, Eurofins Genomics could strengthen its offerings to the synthetic biology market.

EdiGene has developed a diploid library of 2,800 single clonal knockout cell lines, targeting 2,600 genes in commonly used human cancer cell lines.

Additionally, Cancer Genetics noted that last week it sold off its clinical laboratory business to siParadigm, a specialty reference laboratory, for about $1 million.

The assets include intellectual property relevant to iPSC-based phenotypic drug discovery and an existing product business around iPSC-derived cells.

Revolution Medicines had been looking to sell Warp Drive's genomic drug discovery platform and microbial genome database since acquiring them in 2018.

Caprion said that the acquisition helps it acquire expertise in the analysis of myeloid-derived suppressor cells and expand its geographic coverage.